Author information

¹UNC Liver Center, University of North Carolina, Chapel Hill, NC.

²Target RWE, Durham, NC.

³University of Birmingham, Birmingham, UK.

⁴German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Dusseldorf.

⁵Division of Gastroenterology, Department of Medicine, University of California at San Diego, CA.

⁶Division of Gastroenterology and Hepatology, Saint Louis University.

Abstract

Introduction: This study investigates the applicability of the new MASLD nomenclature to the real-world TARGET-NASH US adult cohort.

Methods: The new MASLD/MASH nomenclature was applied to patients enrolled with pragmatic diagnoses of NAFL, NASH and NASH cirrhosis and concordance was determined between the definitions.

Results: 99% of TARGET-NASH participants met the new MASLD diagnostic criteria. 1484/1541 (96.3%, kappa 0.974) NAFL patients (MASL), 2195/2201 (99.7%, kappa 0.998) NASH patients (MASH), and 1999/2003 (99.8%, kappa 0.999) NASH cirrhosis patients met the new criteria.

Conclusion: The new MASLD nomenclature is highly concordant with the prior TARGET-NASH pragmatic definitions.